CJC-1295 Whitout DAC 5mg+Ipamorelin 5mg

الوصف

The CJC-1295 Without DAC 5mg + Ipamorelin 5mg blend is a widely researched peptide combination combining a short-acting growth hormone-releasing hormone (GHRH) analog (CJC-1295 No DAC, also known as Mod GRF 1-29) with a selective growth hormone secretagogue (Ipamorelin, a ghrelin mimetic GHRP). This duo is studied for its synergistic ability to amplify pulsatile endogenous growth hormone (GH) release from the pituitary gland in a more physiological manner than single peptides alone. CJC-1295 Without DAC provides a brief but potent GHRH signal to prime the pituitary, while Ipamorelin selectively triggers GH secretion with minimal elevation of cortisol, prolactin, or appetite—creating a cleaner, more efficient GH pulse profile compared to other GHRP/GHRH stacks. In preclinical research and extensive anecdotal reports from wellness, anti-aging, and performance communities, this blend is associated with potential benefits including increased lean muscle mass and strength, faster recovery from intense training or injury, enhanced fat metabolism (especially visceral and stubborn fat), improved sleep quality and deeper REM cycles, better skin elasticity and joint health, increased bone density, elevated energy levels, and overall metabolic optimization. The typical research protocol involves reconstituting the 10mg vial (5mg CJC-1295 No DAC + 5mg Ipamorelin) with bacteriostatic water and administering 100-300 mcg of the blend (often 1:1 ratio, e.g., 150-200 mcg each peptide) via subcutaneous injection 2-3 times daily—commonly upon waking, post-workout, and before bed—to maximize GH pulses while avoiding receptor desensitization. Cycles usually last 8-12 weeks followed by equal time off. Many users report noticeable improvements in body composition, recovery speed, and vitality within the first few weeks when combined with proper nutrition, resistance training, and sleep hygiene. However, this combination is not FDA-approved for any therapeutic, anti-aging, performance enhancement, or medical use as of 2026—both peptides remain investigational research chemicals, with the FDA listing certain related substances as presenting significant safety risks for human compounding or use. Human data is limited to anecdotal experiences, small observational reports, and extrapolations from animal studies—no large-scale randomized controlled trials exist to confirm long-term efficacy, safety, or dosing in people. Reported side effects are generally mild (injection-site irritation, temporary water retention, flushing, headaches, lightheadedness, fatigue, or mild hunger with Ipamorelin), but potential risks include hormonal imbalances, insulin sensitivity changes, joint discomfort from elevated GH/IGF-1, unknown long-term effects, and immunogenicity concerns with prolonged use. The blend is prohibited by WADA for athletes and should never be used without supervision from a qualified healthcare provider experienced in peptides, as self-administration carries risks of contamination from unregulated sources, improper reconstitution/dosing, adverse reactions, or legal issues. Prioritize evidence-based strategies for fitness, recovery, or hormone support goals—consult a professional to evaluate suitability, source from reputable compounding pharmacies if considered under medical guidance (where permitted), and remain informed on regulatory or emerging research updates. This blend is not a substitute for proven medical treatments or lifestyle interventions.

ALSO SEE